<DOC>
	<DOCNO>NCT01266083</DOCNO>
	<brief_summary>The purpose study determine whether WT1 vaccine cause immune response safe able keep leukemia come back . While vaccine use infectious disease like smallpox measles , idea use vaccine cancer like AML/ALL really new use idea vaccines.The WT-1 vaccine make protein piece immune system recognize abnormal . The doctor think WT-1 protein important AML/ALL use lab test still able find bone marrow . By attack small amount protein hope get rid small amount AML still body .</brief_summary>
	<brief_title>Trial WT-1 Analog Peptide Vaccine Patients With Acute Myeloid Leukemia ( AML ) Acute Lymphoblastic Leukemia ( ALL )</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Morphologic confirmation diagnosis AML ALL MSKCC Patients complete induction therapy , achieve 1st CR complete planned postremission therapy . Patients candidate allogeneic stem cell transplantation . For purpose study , patient candidate allogeneic stem cell transplantation shall define 1 ) meet eligibility criterion open allogeneic transplant protocol 2 ) suitable available HLA match donor available 3 ) refuse undergo stem cell transplantation 4 ) patient whose disease characterize `` good risk '' feature ( For AML follow cytogenetic subtypes : ( 8 ; 21 ) , inv ( 16 ) , ( 16 ; 16 ) , ( 15 ; 17 ) , normal karyotype mutate NPM1 negative tandem duplication FLT3 . For ALL : T cell phenotype B lineage disease exclusive ( 9 ; 22 ) ( 4 ; 11 ) allogenic stem cell transplantation 1st CR would offer standard care . Alternatively , patient great equal 60 year age achieve 1st CR postremission chemotherapy plan may enrol Patients must document WT1 + disease . For purpose study , define detectable presence WT1 transcript via RTPCR bone marrow perform MSKCC within 4 week prior administration first dose vaccine . Patients must within 2 year achieve CR follow chemotherapy At least 4 week must elapse patient 's last chemotherapy radiation treatment first vaccination . Age ≥ 18 year Karnofsky performance status ≥ 50 % Hematologic parameter : Absolute neutrophil count ( ANC ) ≥ 1000/μl Platelets &gt; 50k/ μl Biochemical parameter : Total bilirubin ≤ 2.0 mg/dl AST ALT ≤ 2.5 x upper limit normal Creatinine ≤ 2.0 mg/dl Pregnant lactate woman Patients document evidence leptomeningeal disease Patients undergone autologous allogeneic stem cell transplantation Patients active infection require systemic antimicrobial Patients take systemic corticosteroid Patients serious unstable medical illness</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>MONTANIDE ISA 51</keyword>
	<keyword>WT1 PEPTIDE SPECIFIC T CELLS</keyword>
	<keyword>vaccine</keyword>
	<keyword>10-143</keyword>
</DOC>